Mineralys Therapeutics Presents New Late-Breaking Data from Transform-HTN Open-Label Extension Trial of Lorundrostat in Hypertension at AHA Scientific Sessions 2026

Mineralys Therapeutics announced positive long-term results from the Transform-HTN open-label extension trial of lorundrostat, demonstrating sustained blood pressure reduction of 17.8 mmHg at Week 48, with 56% of participants achieving systolic blood pressure below 130 mmHg. The drug was well tolerated with no new safety concerns. The FDA review is underway with a PDUFA target date of December 22, 2026.